Skip to main content
. 2022 Feb 28;3(2):480–483. doi: 10.1002/jha2.402

FIGURE 1.

FIGURE 1

Kaplan–Meier estimates of the time to the first SRE on this study. The proportion of patients without SRE according to the disease status at the first administration of denosumab, NDMM (N = 52, solid line) and RRMM (N = 23, dotted line)